Abstract
Our knowledge of diastolic heart failure (DHF) is still limited with regard to pathophysiology, diagnosis and clinical treatment. Amongst others, LV dyssynchrony was suggested to be an additional factor involved in the pathogenesis of subgroup of patients with DHF. In 20-30% of patients with DHF a systolic LV dyssynchrony could be detected and about 20% DHF patients evidenced a diastolic dyssyncrony. Both systolic and diastolic dyssynchrony may contribute to the impairment of cardiac function and clinical manifestation in DHF. Opposite to the systolic heart failure, wide QRS complex is uncommon which incriminates that dyssynchrony in DHF is rather related to regional disperse in contractility than to electromechanical coupling delay. Asynchronous LV relaxation and impairment of ventricular restoring forces may also impair the LV filing and lead to a diastolic dyssynchrony. Particularly in patients with preserved LV contractility mechanical LV dyssynchrony induces energy wastage and consequently reduces cardiac reserves. However, up to date it is not clear to what degree LV dyssynchrony is involved in the pathomechanisms of this subpopulation of DHF.
Keywords: Heart failure, diastole, LV dyssynchrony, tissue doppler, strain rate imaging, resynchronization
Current Pharmaceutical Biotechnology
Title:Diastolic Heart Failure and LV Dyssynchrony
Volume: 13 Issue: 13
Author(s): Mario Kasner, Dirk Westermann, Heinz-Peter Schultheiss and Carsten Tschope
Affiliation:
Keywords: Heart failure, diastole, LV dyssynchrony, tissue doppler, strain rate imaging, resynchronization
Abstract: Our knowledge of diastolic heart failure (DHF) is still limited with regard to pathophysiology, diagnosis and clinical treatment. Amongst others, LV dyssynchrony was suggested to be an additional factor involved in the pathogenesis of subgroup of patients with DHF. In 20-30% of patients with DHF a systolic LV dyssynchrony could be detected and about 20% DHF patients evidenced a diastolic dyssyncrony. Both systolic and diastolic dyssynchrony may contribute to the impairment of cardiac function and clinical manifestation in DHF. Opposite to the systolic heart failure, wide QRS complex is uncommon which incriminates that dyssynchrony in DHF is rather related to regional disperse in contractility than to electromechanical coupling delay. Asynchronous LV relaxation and impairment of ventricular restoring forces may also impair the LV filing and lead to a diastolic dyssynchrony. Particularly in patients with preserved LV contractility mechanical LV dyssynchrony induces energy wastage and consequently reduces cardiac reserves. However, up to date it is not clear to what degree LV dyssynchrony is involved in the pathomechanisms of this subpopulation of DHF.
Export Options
About this article
Cite this article as:
Kasner Mario, Westermann Dirk, Schultheiss Heinz-Peter and Tschope Carsten, Diastolic Heart Failure and LV Dyssynchrony, Current Pharmaceutical Biotechnology 2012; 13 (13) . https://dx.doi.org/10.2174/1389201011208062539
DOI https://dx.doi.org/10.2174/1389201011208062539 |
Print ISSN 1389-2010 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4316 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
The Influence of Genetic Variations and Drug Interactions Based on Metabolism of Antidepressants and Anticonvulsants
Current Drug Metabolism Pleiotropic Effects of HDL: Towards New Therapeutic Areas for HDL-Targeted Interventions
Current Molecular Medicine The Cytoplasmic Rhodopsin-Protein Interface: Potential for Drug Discovery
Current Drug Targets Pentraxins and Atherosclerosis: The Role of PTX3
Current Pharmaceutical Design The Preclinical Bases of the Rational Combination of Paclitaxel and Antiangiogenic Drugs
Clinical Cancer Drugs Immunophilins and Coupled Gating of Ryanodine Receptors
Current Topics in Medicinal Chemistry Inhibitory Role of Resveratrol in the Development of Profibrogenesis and Fibrosis Mechanisms
Immunology, Endocrine & Metabolic Agents in Medicinal Chemistry (Discontinued) Role of Toxicogenomics in the Development of Safe, Efficacious and Novel Anti-microbial Therapies.
Infectious Disorders - Drug Targets Aldose Reductase: A Multi-disease Target
Current Enzyme Inhibition Oxidative Stress and Cardiac Remodeling: An Updated Edge
Current Cardiology Reviews Artepillin C Induces Selective Oxidative Stress and Inhibits Migration and Invasion in a Comprehensive Panel of Human Cervical Cancer Cell Lines
Anti-Cancer Agents in Medicinal Chemistry Medicinal Chemistry of Drugs Used in Diabetic Cardiomyopathy
Current Medicinal Chemistry The cAMP-Dependent Protein Kinase Pathway as Therapeutic Target – Possibilities and Pitfalls
Current Topics in Medicinal Chemistry Obesity-Induced Cerebral Hypoperfusion Derived from Endothelial Dysfunction: One of the Risk Factors for Alzheimer's Disease
Current Alzheimer Research Control of Risk Factors for Cardiovascular Disease among Multinational Patient Population in the Arabian Gulf
Current Vascular Pharmacology The 9p21 Locus and its Potential Role in Atherosclerosis Susceptibility; Molecular Mechanisms and Clinical Implications
Current Pharmaceutical Design Glucose-6-phosphate Dehydrogenase: a Biomarker and Potential Therapeutic Target for Cancer
Anti-Cancer Agents in Medicinal Chemistry Recent Advances in Sepsis Research: Novel Biomarkers and Therapeutic Targets
Current Medicinal Chemistry Antiplatelet and Antithrombin Strategies in Acute Coronary Syndrome: State-Of-The-Art Review
Current Cardiology Reviews Risk Stratification for Sudden Cardiac Death: Current Approaches and Predictive Value
Current Cardiology Reviews